Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Recommendation of “Hold” by Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given an average rating of “Hold” by the five analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $8.00.

A number of brokerages recently weighed in on SRTS. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. Zacks Research raised Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd. Finally, Wall Street Zen upgraded Sensus Healthcare from a “sell” rating to a “hold” rating in a research note on Saturday.

Sensus Healthcare Price Performance

Sensus Healthcare stock opened at $3.79 on Wednesday. Sensus Healthcare has a one year low of $3.03 and a one year high of $9.08. The business’s fifty day moving average is $3.78 and its 200 day moving average is $3.94. The stock has a market capitalization of $62.23 million, a PE ratio of -19.95 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. The business had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.31 million. Sensus Healthcare had a negative net margin of 8.44% and a negative return on equity of 5.67%. As a group, sell-side analysts expect that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Insider Activity

In other Sensus Healthcare news, Director Eric Sachetta purchased 7,000 shares of Sensus Healthcare stock in a transaction dated Friday, November 21st. The stock was purchased at an average price of $3.93 per share, with a total value of $27,510.00. Following the transaction, the director directly owned 140,113 shares of the company’s stock, valued at $550,644.09. This trade represents a 5.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joseph C. Sardano acquired 25,000 shares of the stock in a transaction dated Tuesday, November 18th. The stock was acquired at an average price of $4.03 per share, for a total transaction of $100,750.00. Following the purchase, the chief executive officer directly owned 1,200,293 shares in the company, valued at approximately $4,837,180.79. This trade represents a 2.13% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 36,500 shares of company stock worth $147,570 over the last three months. Insiders own 8.90% of the company’s stock.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the business. American Century Companies Inc. increased its stake in shares of Sensus Healthcare by 12.7% in the 1st quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock worth $106,000 after purchasing an additional 2,520 shares in the last quarter. Trexquant Investment LP purchased a new stake in Sensus Healthcare in the first quarter worth about $93,000. Acadian Asset Management LLC increased its position in Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock worth $2,225,000 after buying an additional 122,746 shares in the last quarter. Kingstone Capital Partners Texas LLC bought a new position in shares of Sensus Healthcare in the second quarter worth about $3,170,000. Finally, Chapin Davis Inc. lifted its position in shares of Sensus Healthcare by 66.7% during the 2nd quarter. Chapin Davis Inc. now owns 25,000 shares of the company’s stock valued at $118,000 after buying an additional 10,000 shares in the last quarter. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.